Transcriptomics

Dataset Information

0

ZFP91 and IKZF1 Cooperatively Promote IMiD Resistance in T-Cell Lymphomas


ABSTRACT: The immunomodulatory (IMiD) agents, such as lenalidomide, are highly effective treatment for several B cell lymphomas but have poor efficacy in T cell lymphomas (TCLs). Here, we show that IKZF1 is a key drug target and vulnerability in lenalidomide sensitive TCL cells. However, TCLs are largely resistant and become less dependent on IKZF1. Instead, ZPF91 functions as a transcription factor (TF) and coregulates cell survival with IKZF1 in TCL cells that develop resistance to lenalidomide. Aberrant upregulation of CSNK2B, which leads to c-Jun inactivation, contributes to an enhanced TF activity of ZFP91 and suppresses immune activation triggered by lenalidomide. Although ZFP91 can be better targeted by pomalidomide compared to lenalidomide, an inefficient degradation of IKZF1 and ZFP91 widely exists among IMiD-resistance TCLs. A novel CELMoD agent CC-92480, with markedly increased potency and similar substrate selectivity, can overcome IMiD-resistance across multiple TCL subtypes by near complete degradation of IKZF1 and ZFP91.

ORGANISM(S): Homo sapiens

PROVIDER: GSE172505 | GEO | 2022/04/21

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-10-30 | GSE246435 | GEO
2023-10-30 | GSE246429 | GEO
2023-10-30 | GSE246426 | GEO
| PRJNA723579 | ENA
2017-03-01 | GSE94728 | GEO
2017-05-29 | PXD005849 | Pride
2017-05-29 | PXD005857 | Pride
2017-02-10 | GSE77877 | GEO
2017-02-10 | GSE77876 | GEO
2017-02-10 | GSE77875 | GEO